Comparative

Human disease

Rett syndrome

MONDO:0010726

Mondo defines it as: “A severe neurodevelopmental disorder affecting the central nervous system.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
2406 Rett syndrome, MECP2-related OMIA's OMIM numbers 3 Target evidence 84.9

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Human gene Score Evidence
MECP2 0.88 4,583

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Trofinetide None of these genes Approved
Blarcamesine None of these genes Phase 3
Cannabidiol None of these genes Phase 3
Dextromethorphan None of these genes Phase 3
Donepezil None of these genes Phase 3
Fenfluramine None of these genes Phase 3
Sarizotan None of these genes Phase 2/3
Desipramine None of these genes Phase 2
Glatiramer Acetate None of these genes Phase 2
Ketamine None of these genes Phase 2
Lovastatin None of these genes Phase 2
Mecasermin None of these genes Phase 2
Mirtazapine None of these genes Phase 2
Tridecanoate None of these genes Phase 2
Triheptanoin None of these genes Phase 2
Ubidecarenone None of these genes Phase 2
Vatiquinone None of these genes Phase 2
Fingolimod None of these genes Phase 1/2
Vorinostat None of these genes Phase 1
Esketamine None of these genes Early phase 1
Topiramate None of these genes Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.